SAN DIEGO, April 17, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate to severe Parkinson’s disease (PD). Aspen Neuroscience is a private biotechnology company developing personalized regenerative therapies.
Read the full press release here
Related posts:
BlueRock’s neuronal stem cell therapy for Parkinson’s disease is first to show positive results in Phase I clinical study
Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients
California’s Stem Cell Agency Invests in Phase 3 Clinical Trial to Help Kidney Transplant Patients